On systems and control approaches to the therapeutic gain

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Radivoyevitch, Tomas ^a   Loparo, Kenneth A ^b   Jackson, Robert C ^c   Sedwick, W David ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Case Western Reserve University   (United States)

^c CYCLACEL LTD   (United Kingdom)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DNA; IMATINIB; METHOTREXATE; PEMETREXED; URIDINE; FOLIC ACID; IDOXURIDINE; ONCOPROTEIN; RADIOSENSITIZING AGENT; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ARTICLE; B CELL LEUKEMIA; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CELL DEATH; CELL KILLING; CHILDHOOD LEUKEMIA; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; LEARNING; MALIGNANT NEOPLASTIC DISEASE; MARKUP LANGUAGE; MATHEMATICAL MODEL; MISMATCH REPAIR; PROGNOSIS; SYSTEMS BIOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; ACUTE LYMPHOCYTIC LEUKEMIA; BIOLOGICAL MODEL; COMPARATIVE STUDY; DNA REPAIR; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; SYSTEMS THEORY;

ANTINEOPLASTIC AGENTS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FUSION PROTEINS, BCR-ABL; HUMANS; IDOXURIDINE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENE PROTEINS, FUSION; RADIATION-SENSITIZING AGENTS; SYSTEMS BIOLOGY; SYSTEMS THEORY;

EID: 33745612128     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-104     Document Type: Article

References (54)

1. The Integrative Cancer Biology Program [http://icbp.nci.nih.gov/]
2. Jackson RC: Kinetic simulation of anticancer drug interactions. Int J Biomed Comput 1980, 11(3):197-224.
3. Morrison PF, Allegra CJ: Folate cycle kinetics in human breast cancer cells. J Biol Chem 1989, 264(18): 10552-10566.
4. Novak B, Tyson JJ: A model for restriction point control of the mammalian cell cycle. J Theor Biol 2004, 230(4):563-579.
5. Ciliberto A, Novak B, Tyson A: Steady states and oscillations in the p53/ Mdm2 network. Cell Cycle 2005, 4(3):488-493.
6. Ma L, Wagner J, Rice JJ, Hu W, Levine AJ, Stolovitzky GA. A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A 2005, 102(40):14266-14271.
7. Lipniacki T, Paszek P, Brasier AR, Luxon B, Kimmel M: Mathematical model of NF-kappaB regulatory module. J Theor Biol 2004, 228(2):195-215.
8. Sha W, Moore J, Chen K, Lassaletta AD, Yi CS, Tyson JJ, Sible JC: Hysteresis drives cell-cycle transitions in Xenopus laevis egg extracts. Proc Natl Acad Sci U S A 2003, 100(3):975-980.
9. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L: Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999, 59(19):4770-4775.
10. Hirsch MW, Smale S: Differential equations, dynamical systems, and linear algebra. New York. Academic Press; 1974.
11. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novere N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, Nakayama Y, Nelson MR, Nielsen PF, Sakurada T, Schaff JC, Shapiro BE, Shimizu TS, Spence HD, Stelling J, Takahashi K, Tomita M, Wagner J, Wang J: The systems biology markup language (SBML): a medium for representation and exchange of bio-chemical network models. Bioinformatics 2003, 19(4):524-531.
12. Systems Biology Markup Language [http://sbml.org]
13. Ihaka R, Gentleman R: R:a language for data analysis and graphics. Journal of Computational and graphical statistics 1996, 5:299-314.
14. MATLAB: version 7.0. Mathworks Inc., Natick, MA. 7.0 2004.
15. Tong FK, Chow S, Hedley D: Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 2006.
16. Yau CY, Wheeler JJ, Sutton KL, Hedley DW: Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the P13K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005, 65(4):1497-1504.
17. Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL: Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry A 2003, 54(2): 75-88.
18. Chow S, Patel H, Hedley DW: Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001, 46(2): 72-78.
19. Danna EA, Nolan GP. Transcending the biomarker mindset-deciphering disease mechanisms at the single cell level. Curr Opin Chem Biol 2006, 10(1):20-27.
20. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP: Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005, 308(5721):523-529.
21. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP: Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118(2):217-228.
22. Krutzik PO, Irish JM, Nolan GP, Perez OD: Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004, 110(3):206-221.
23. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, Kamada N, Dohy H, Matsuo T, Matsui T: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994, 137(2 Suppl): S68-S97.
24. Inskip PD, Kleinerman RA, Stovall M, Cookfair DL, Hadjimichael O, Moloney WC, Monson RR, Thompson WD, Wactawski-Wende J, Wagoner JK: Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease. Radiat Res 1993, 135(1):108-124.
25. Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET: Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987, 79(6):1295-1311.
26. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasald M, Izumi S: Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994, 137(2 Suppl):S17-67.
27. Kailath T: Linear Systems. Englewood Cliffs, NJ: Prentice-Hall; 1980.
28. Isidori A: Nonlinear Control Systems. 3rd edition. Springer-Verlag; 1995.
29. Athans M, Falb PL: Optimal control; an introduction to the theory and its applications. New York.: McGraw-Hill; 1966.
30. Bryson AE, Ho YC: Applied Optimal Control. New York. Hemisphere Publishing Corporation; 1975.
31. Swan GW: Role of optimal control theory in cancer chemotherapy. Math Biosci 1990, 101(2):237-284.
32. Martin R, Teo KL Optimal control of drug administration in cancer chemotherapy. River Edge, N.J.: World Scientific; 1994.
33. SBMLR [http://epbi-radivot.cwru.edu/SBMLR/]
34. Radivoyevitch T: A two-way interface between limited Systems Biology Markup Language and R. BMC Bioinformatics 2004, 5(1):190.
35. Radivoyevitch Lab [http://epbi-radivot.cwru.edu/]
36. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1(2):133-143.
37. Radivoyevitch T: Folate system correlations in DNA microarray data. BMC Cancer 2005, 5:95.
38. ICB approaches to therapeutic gain [http://epbiradivot.cwru.edu/ ICBtherap/]
39. Erikson RL, Szybalski W: Molecular Radiobiology of Human Cell Lines. V. Comparative Radiosensitizing Properties of 5-Halodeoxycytidines and 5-Halodeoxyuridines. Radiat Res 1963, 20:252-262.
40. Djordjevic B, Szybalski W. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med 1960, 112:509-531.
41. Fornace AJ Jr, Dobson PP, Kinsella TJ: Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990, 18(4):873-878.
42. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ Jr: Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987, 13(5): 733-739.
43. Berry SE, Davis TW, Schupp JE, Hwang HS, de Wind N, Kinsella TJ: Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 2000, 60(20):5773-5780.
44. Berry SE, Garces C, Hwang HS, Kunugi K, Meyers M, Davis TW, Boothman DA, Kinsella TJ: The mismatch repair protein, hMLHI, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 1999, 59(8): 1840-1845.
45. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 1997, 278(5340):1059-1064.
46. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998, 339(9):605-615.
47. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifollate LY231514 (MTA). Adv Enzyme Regul 1998, 38:135-152.
48. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83(5):1179-1187.
49. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling DA, Kinsella TJ: Inhibition of base excision repair potentiates iododeoxyurldine-induced cytotoxicity and radiosensitization. Cancer Res 2003, 63(4):838-846.
50. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100(17):9991-9996.
51. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon P, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25): 1937-1947.
52. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warrike R, Staudt LM: Distinct types of diffuse large B-cell lymphoma, identified by gene expression profiling. Nature 2000, 403(6769):503-511.
53. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl ] Med 2004, 350(18):1828-1837.
54. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature 2005, 435(7046):1267-1270.